Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on
study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in
chronic phase (CML-CP) who have a suboptimal molecular response to imatinib at 18 months or
later.